Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of OD-07656 and Subsequent Vedolizumab in Moderately to Severely Active Ulcerative Colitis
2024-520201-39-00Phase 2Authorised
- Sponsor
- Odyssey Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of OD-07656 in autoimmune colitis (2 arms), sponsored by Odyssey Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events, Changes in safety parameters and 1 more. Planned start Jun 2025; status: authorised.
02
Drugs
OD-07656
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-520201-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520201-39-00.